.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a median follow-up of 11 months, patients with metastatic gastrointestinal lumps that got biomarker-matched therapies based upon distributing lump DNA profiling presented a more significant professional perk than those acquiring unmatched treatment.